北京若生智能科技有限公司
Drug Database
MO

mometasone furoate (Monovo / H527722 / Mundoson)

✓ Approved

Almirall, S.A · NR3C1 · 小分子

什么是 mometasone furoate？

mometasone furoate 是一种小分子，由Almirall, S.A研发。该药已获批，用于治疗相关适应症，给药途径：Topical。

药物档案

商品名Monovo, H527722, Mundoson
公司Almirall, S.A
药物类别小分子
分子靶点NR3C1, NR3C2
给药途径Topical
状态Approved
来源： ClinicalTrials.gov, Almirall, S.A

作用机制

分子靶点

mometasone furoate 作用于 2 个分子靶点：

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
NR3C2nuclear receptor subfamily 3 group C member 2 (NR3C2VIT, MR)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

mometasone furoate 针对 3 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Skin and subcutaneous tissue disordersDermatitis allergic✓ Approved
Skin and subcutaneous tissue disordersDermatitis atopic✓ Approved
Skin and subcutaneous tissue disordersPsoriasis✓ Approved

相关研究文献

PubMedJournal of clinical medicine2026-10-27

Real-World Effects of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Chinese Patients with Asthma.

Li Anqi A, Pan Zhouxian Z, Liu Juan J, Li Lun L et al.

Background/Objectives: Asthma is a heterogeneous chronic inflammatory airway disease. In China, achieving rapid asthma control remains a major challenge, and a substantial proportion of patients remain inadequately controlled despite regular use of standard inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) therapy. Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) has demonstrated clinical efficacy in trials, but its real-world effectiveness and safety in China remain insufficiently characterized. This study evaluated FF/UMEC/VI (100/62.5/25 μg) in Chinese patients with uncontrolled asthma. Methods: This retrospective study included patients with asthma treated with FF/UMEC/VI at the Department of Allergy, Peking Union Medical College Hospital, between July 2021 and March 2024. The cohort included patients with no prior inhaled medication, irregular prior inhaled therapy, or regular prior inhaled therapy with inadequate control, reflecting a real-world spectrum of patients requiring treatment intensification. Assessments were performed at baseline and 1, 3, and 6 months after treatment initiation. The primary endpoint was the change in forced expiratory volume in 1 s (FEV1) at 1 month. Secondary outcomes included changes in FEV1, percent predicted FEV1, and FEV1/forced vital capacity (FEV1/FVC), and safety. Results: Thirty patients were analyzed. FEV1 increased significantly at 1 month and remained above baseline at 3 and 6 months. Percent predicted FEV1 and FEV1/FVC also improved significantly at all follow-up visits. Maintenance therapy was reduced in 53.3% of patients. No serious adverse events occurred; reported events were mainly local throat discomfort and increased sputum production. Conclusions: In real-world practice, FF/UMEC/VI was associated with improved lung function measures in Chinese patients, including previously untreated, irregularly treated, and regularly treated but uncontrolled patients, with an acceptable safety profile. Larger prospective studies are warranted to confirm its long-term effectiveness and identify appropriate patient populations in China.

PMID 42941503
阅读全文 →
PubMedAdvances in respiratory medicine2026-10-26

Deciphering the Benefits and Risks of Single-Inhaler Triple Therapy in COPD.

Kopitovic Ivan I, Dimic-Janjic Sanja S, Stjepanovic Mihailo M, Hromis Sanja S et al.

Single-inhaler triple therapy (SITT) combines an inhaled corticosteroid (ICS; for example, fluticasone furoate, budesonide, or beclometasone dipropionate), a long-acting β2-agonist (LABA; for example, vilanterol or formoterol fumarate), and a long-acting muscarinic antagonist (LAMA; for example, umeclidinium or glycopyrronium bromide) in one device. Triple pharmacological therapy reduces exacerbations in selected patients with chronic obstructive pulmonary disease (COPD), but its effects on mortality and cardiovascular outcomes remain uncertain. This structured narrative review summarizes randomized trials, observational comparative-effectiveness studies, target trial emulations, systematic reviews, and health technology assessments published between 2015 and 2026. We grouped the evidence by comparator: LABA/LAMA, ICS/LABA, multiple-inhaler triple therapy (MITT), and ICS continuation versus withdrawal, because each comparison addresses a different clinical question. Pivotal trials and evidence syntheses consistently showed fewer moderate-to-severe exacerbations with triple therapy, with reported rate ratios of approximately 0.69-0.93. Mortality signals from IMPACT and ETHOS are clinically important, but previous ICS use and ICS withdrawal among participants assigned to ICS-free comparators make these findings difficult to interpret. Observational cardiovascular findings are also uncertain because residual confounding, treatment selection, exposure misclassification, outcome misclassification, and differences in baseline disease severity limit causal interpretation. Compared with MITT, the main advantages of SITT are simpler treatment and possible improvements in adherence and persistence, not greater pharmacological potency. Treatment decisions should consider exacerbation history, repeated blood eosinophil counts, pneumonia risk, cardiovascular disease, previous ICS exposure and response, inhaler technique, device suitability, and patient preference. Trials in patients with documented absence of previous ICS use and well-designed target trial emulations are needed to determine whether the observed mortality and cardiovascular associations are causal.

PMID 42930048
阅读全文 →
PubMedChemSusChem2026-10-20

Valorization of Pentose-Derived Furoates Into 2,5-Furandicarboxylic Acid via Friedel-Crafts Acylation and Amoco Oxidation.

Thiyagarajan Shanmugam S, Angelici Carlo C, van Es Daan S DS, Gruter Gert-Jan M GM

5-Hydroxymethylfurfural (5-HMF), derived from edible C6 sugars, is widely recognized as a key intermediate in established synthetic routes toward 2,5-furandicarboxylic acid (2,5-FDCA), a promising biobased platform chemical. However, reliance on food-based feedstocks presents sustainability and ethical concerns. In this context, nondigestible C5 sugars such as xylose and arabinose-abundant in lignocellulosic agricultural residues-offer an attractive alternative that avoids competition with food resources. Herein, we present a two-step synthetic strategy for the synthesis of 2,5-FDCA starting from 2-furoic acid, a readily accessible derivative of C5 sugars. The first step involves a Friedel-Crafts acylation of methyl 2-furoate using acetic anhydride under acid catalysis, yielding methyl 5-acetyl-2-furoate (1) as the intermediate. Catalyst screening revealed that ZnCl2 achieves complete selectivity toward the desired intermediate at 36% substrate conversion, whereas methanesulfonic acid (MSA) provides higher conversion (59%) with 80% selectivity to (1). In the second step, oxidation of the intermediate under industrially relevant Amoco conditions, employing Co/Mn/Br-based catalytic systems, yields 2,5-FDCA (2) and its monomethyl ester (2a) with combined yields exceeding 95%. Systematic variation of catalyst composition highlights the critical role of the Co/Mn/Br synergy in achieving high oxidation efficiency. This work represents a promising proof-of-concept route that demonstrates accessibility of 2,5-FDCA from pentose-derived intermediates, contributing to enhancing the development of renewable alternatives to petroleum-derived monomers.

PMID 42899486
阅读全文 →
PubMedEar, nose, & throat journal2026-10-09

Petrous Apex Mucocele: A Case Report and Literature Review.

Trifunoski Dimitar D, Urbančič Jure J, Felbabić Tomislav T, Vozel Domen D

BackgroundA petrous apex mucocele is a rare benign cystic lesion that can present with symptoms due to pressure on surrounding structures, including the internal carotid artery, Meckel's cave and the fifth and sixth cranial nerves, as well as the cavernous sinus region and inner ear.MethodsA 36-year-old male presented with 8 months of diplopia when looking to the right, a right-sided temporoparietal headache, and paresthesia in the right half of his face. An MRI revealed a 26 × 32 × 37 mm lesion in the right petrous apex. The lesion's signal characteristics were most consistent with a mucocele. We performed an endoscopic endonasal transclival marsupialization and created a wide drainage opening, which we supported by inserting a stent containing mometasone furoate.ResultsThe postoperative course was marked by transient arterial hypertension, which required antihypertensive treatment. Postoperative imaging studies revealed no intracranial complications and confirmed that the drainage pathway remained patent.ConclusionIn the differential diagnosis of lesions in the medial portion of the petrous apex, a mucocele should be considered. In appropriately selected cases, endoscopic endonasal marsupialization can be an effective option. To maintain postoperative patency of the drainage pathway, an implant containing mometasone furoate may also be used.

PMID 42853696
阅读全文 →
PubMedPediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology2026-10-09

Intranasal corticosteroids in pediatric airway inflammation: From pharmacokinetics and evidence to optimized clinical practice.

Papadopoulou Athina A, Papadopoulos Marios M, Tsabouri Sophia S

Intranasal corticosteroids (INS) are widely recommended as first-line therapy for pediatric upper airway disorders due to their potent local anti-inflammatory effects and favorable safety profile. This narrative review evaluates current evidence regarding the pharmacologic properties, clinical efficacy, and safety of INS in children with allergic rhinitis (AR), adenoid hypertrophy (ADH), obstructive sleep apnea (OSA) or sleep-disordered breathing (SDB), otitis media with effusion (OME), and rhinosinusitis (RS). A structured literature search of PubMed, EMBASE, and Cochrane databases (2015-2025) identified randomized controlled trials, observational studies, systematic reviews, and meta-analyses assessing indications, efficacy outcomes, and adverse events. Evidence consistently supports INS as the most effective pharmacologic therapy for pediatric AR, with significant improvements in symptom scores and quality of life. In ADH and mild OSA/SDB, INS may reduce nasal obstruction and decrease adenoid size, potentially lowering the need for surgical intervention. Data for OME are inconsistent, and routine use is not universally recommended. In acute and chronic RS, INS demonstrates benefit, particularly when allergic inflammation predominates. Pharmacokinetic differences among agents influence safety. Newer molecules such as fluticasone propionate, fluticasone furoate, and mometasone furoate exhibit low systemic bioavailability and high receptor affinity, minimizing hypothalamic-pituitary-adrenal axis suppression. Local adverse effects are generally mild and comparable to placebo. Epistaxis is a recognized local adverse effect, although pediatric data do not demonstrate a significant increase compared with placebo. Available data suggest minimal, clinically insignificant effects on growth velocity when recommended doses are used. Overall, INS remain a cornerstone of AR therapy, with well-established efficacy and a favorable safety profile when appropriately used. There is also supportive and clinically meaningful evidence for their use in selected children with ADH, although the available evidence is heterogeneous. In contrast, evidence for INS in OME, OSA/SDB, and pediatric CRS remains limited or inconsistent and does not currently support their routine use solely for these pediatric upper airway conditions, particularly in the absence of concomitant nasal allergic inflammation.

PMID 42851129
阅读全文 →
PubMedCurrent medical research and opinion2026-10-02

The hidden burden of topical corticosteroid misuse: a systematic review of dermatologic complications.

Alzahrani Ali A

Topical corticosteroids are widely prescribed for their anti-inflammatory, immunosuppressive, and antiproliferative effects in conditions such as atopic and contact dermatitis. However, their rapid symptomatic relief has contributed to misuse, particularly for cosmetic purposes, leading to multiple adverse effects. This study aimed to evaluate complications associated with topical corticosteroid misuse and the contributing factors. Following PRISMA guidelines, a systematic search of PubMed, Scopus, and Web of Science was conducted to identify studies published between January 2016 and January 2026. Eligible studies reported primary data on topical corticosteroid misuse and associated factors. Extracted data included study characteristics, patterns of misuse, complications, prevalence of misuse-related adverse effects, and associated factors. Risk of bias was assessed using the Joanna Briggs Institute critical appraisal checklist. Twenty-three studies involving 8,619 participants were included. Misuse was commonly reported for cosmetic indications, including skin lightening, melasma, acne, and skin fairness. Betamethasone, mometasone, and clobetasol were the most frequently misused agents. Most participants experienced at least one adverse effect, including acneiform eruptions, pigmentation disorders, erythema, and worsening dermatophytosis. Factors associated with misuse included female gender, younger age, poor health-seeking behavior, and over-the-counter availability. Topical corticosteroid misuse is an important public health concern, particularly where potent products are readily available without prescription. Reducing misuse requires prescription-based access to potent topical corticosteroids, pharmacist counselling at dispensing, clinician education on appropriate potency and duration, and targeted public education on cosmetic misuse and potential adverse effects.

PMID 42826358
阅读全文 →

注册免费账户还可查看另外 2141 篇文献

免费注册查看全部文献 →

了解更多mometasone furoate